Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cowen & Co. Maintains Outperform on Crown Castle, Raises Price Target to $152

Cowen & Co. analyst Gregory Williams maintains Crown Castle (NYSE:CCI) with a Outperform and raises the price target from $149 to $152.
byBenzinga Newsdesk
January 27, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Cowen & Co. analyst Gregory Williams maintains Crown Castle (NYSE:CCI) with a Outperform and raises the price target from $149 to $152.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bristol Myers’ Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug

By Vandana Singh
September 7, 10:03 AM
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst (pomalidomide) long after it should have faced competition from generic alternative

BMY